publicly traded on the Stockholm exchange

"Its rare to see aprivate biotechnology company with four promising compounds in phase II clinicaltrials." "Of the six clinical-stage compounds acquired from Roche, Novartis and Syngenta,two are already marketed by other companies in non-competing indications", saidJakob Lindberg, Partner of Investor Growth Capital. "This enables Synosia tobuild on thousands of years of patient experience, significantly reducing thedevelopment risk from a safety perspective." As part of this Series B financing, Jean-Philippe Tripet of Aravis, and GöstaJonsson, independent scientific advisor to Investor Growth Capital, becamemembers of the companys board of directors. In addition, Synosia announced that the following joined the board of directors:Guido Magni, formerly head of global medical science and global drug developmentat Roche for more than 10 years; Harry Welten, Chief Financial Officer ofArpida; Ralf Rosenow, Partner of Blum&Grob Attorneys at Law and GenghisLloyd-Harris, Partner of Abingworth. Thanks to their efforts, we now have astrong portfolio of clinical-stage assets and a sound strategy to develop ourcompounds.

I am also pleased that Mark Moran will continue to play an importantrole as our Chief Medical Advisor". "With this financing, the company has the necessary financial backing to moveits compounds through pivotal phase II clinical trials", commented SynosiaChairman Brad Bolzon. "The support of a group of premier life science investorsclearly validates the quality of this management team and their recentachievements, which is especially gratifying during this uncertain time in thefinancial markets." About Synosia TherapeuticsSynosia Therapeutics develops and intends to commercialise innovative andclinically differentiated products for unmet medical needs in psychiatry andneurology. The privately-owned company has in its pipeline six clinical-stagecompounds acquired through key partnerships with Novartis, Roche and Syngenta.Two of the compounds are marketed drugs being tested in new indications toextend their reach into neurological and psychiatric diseases with high unmetmedical need, including anxiety and Parkinsons disease Synosias headquartersis in Basel, Switzerland. For more information visit Aravis VentureAravis is a Switzerland based venture capital organisation, managing two fundsfocused on life science (Aravis Biotech I & II) and a third fund focused onrenewable energy (Aravis Energy I).

Since 1995, the Aravis management team hasinvested over $600 million in more than 80 companies. Investor Growth CapitalInvestor Growth Capital is the wholly owned venture capital arm of Investor AB(Investor). Investor, publicly traded on the Stockholm exchange, is the largestlisted industrial holding company in Northern Europe. Investor was founded in1916 to continue the Wallenberg family's tradition of financing and buildingbest-in-class companies.